The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease

Current Opinion in Immunology

Volumn 23, Issue 3, 2011, Pages 310-318

  Soldevila, Gloria ^a   Raman, Chander ^b   Lozano, Francisco ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; EFFECTOR CELL; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD5; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; IMMUNE TOLERANCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79957750936     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.03.003     Document Type: Review

References (56)

1. Hardy R.R. B-1 B cells: development, selection, natural autoantibody and leukemia. Curr Opin Immunol 2006, 18:547-555.
2. Resnick D., Pearson A., Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 1994, 19:5-8.
3. Sarrias M.R., Gronlund J., Padilla O., Madsen J., Holmskov U., Lozano F. The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 2004, 24:1-37.
4. Brown M.H., Lacey E. A ligand for CD5 is CD5. J Immunol 2010, 185:6068-6074.
5. Lozano F., Simarro M., Calvo J., Vila J.M., Padilla O., Bowen M.A., Campbell K.S. CD5 signal transduction: positive or negative modulation of antigen receptor signaling. Crit Rev Immunol 2000, 20:347-358.
6. Raman C. CD5, an important regulator of lymphocyte selection and immune tolerance. Immunol Res 2002, 26:255-263.
7. Dennehy K.M., Broszeit R., Ferris W.F., Beyers A.D. Thymocyte activation induces the association of the proto-oncoprotein c-cbl and ras GTPase-activating protein with CD5. Eur J Immunol 1998, 28:1617-1625.
8. Demydenko D. c-Cbl mediated ubiquitylation and regulation of cell surface exposure of CD5. Biochem Biophys Res Commun 2010, 392:500-504.
9. Axtell R.C., Xu L., Barnum S.R., Raman C. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system. J Immunol 2006, 177:8542-8549.
10. Azzam H.S., DeJarnette J.B., Huang K., Emmons R., Park C.S., Sommers C.L., El-Khoury D., Shores E.W., Love P.E. Fine tuning of TCR signaling by CD5. J Immunol 2001, 166:5464-5472.
11. Garaud S., Le Dantec C., Berthou C., Lydyard P.M., Youinou P., Renaudineau Y. Selection of the alternative exon 1 from the cd5 gene down-regulates membrane level of the protein in B lymphocytes. J Immunol 2008, 181:2010-2018.
12. Axtell R.C., Webb M.S., Barnum S.R., Raman C. Cutting edge: critical role for CD5 in experimental autoimmune encephalomyelitis: inhibition of engagement reverses disease in mice. J Immunol 2004, 173:2928-2932\.
13. Friedlein G., El Hage F., Vergnon I., Richon C., Saulnier P., Lecluse Y., Caignard A., Boumsell L., Bismuth G., Chouaib S., et al. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 2007, 178:6821-6827.
14. Dorothee G., Vergnon I., El Hage F., Le Maux Chansac B., Ferrand V., Lecluse Y., Opolon P., Chouaib S., Bismuth G., Mami-Chouaib F. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J Immunol 2005, 174:6888-6897.
15. Gagnon J., Chen X.L., Forand-Boulerice M., Leblanc C., Raman C., Ramanathan S., Ilangumaran S. Increased antigen responsiveness of naive CD8 T cells exposed to IL-7 and IL-21 is associated with decreased CD5 expression. Immunol Cell Biol 2010, 88:451-460.
16. Yang Y., Contag C.H., Felsher D., Shachaf C.M., Cao Y., Herzenberg L.A., Herzenberg L.A., Tung J.W. The E47 transcription factor negatively regulates CD5 expression during thymocyte development. Proc Natl Acad Sci U S A 2004, 101:3898-3902.
17. Ling K.W., van Hamburg J.P., de Bruijn M.J., Kurek D., Dingjan G.M., Hendriks R.W. GATA3 controls the expression of CD5 and the T cell receptor during CD4T cell lineage development. Eur J Immunol 2007, 37:1043-1052.
18. Ryan K.R., McCue D., Anderton S.M. Fas-mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation. J Leukoc Biol 2005, 78:43-50.
19. Ordonez-Rueda D., Lozano F., Sarukhan A., Raman C., Garcia-Zepeda E.A., Soldevila G. Increased numbers of thymic and peripheral CD4(+) CD25(+)Foxp3(+) cells in the absence of CD5 signaling. Eur J Immunol 2009, 39:2233-2247.
20. Dennehy K.M., Broszeit R., Garnett D., Durrheim G.A., Spruyt L.L., Beyers A.D. Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5. Eur J Immunol 1997, 27:679-686.
21. Gary-Gouy H., Harriague J., Bismuth G., Platzer C., Schmitt C., Dalloul A.H. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002, 100:4537-4543.
22. Perez-Chacon G., Vargas J.A., Jorda J., Morado M., Rosado S., Martin-Donaire T., Losada-Fernandez I., Rebolleda N., Perez-Aciego P. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leuk Res 2007, 31:183-193.
23. Gary-Gouy H., Sainz-Perez A., Marteau J.B., Marfaing-Koka A., Delic J., Merle-Beral H., Galanaud P., Dalloul A. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 2007, 179:4335-4344.
24. Sellick G.S., Wade R., Richards S., Oscier D.G., Catovsky D., Houlston R.S. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 2008, 111:1625-1633.
25. Rowley B., Tang L., Shinton S., Hayakawa K., Hardy R.R. Autoreactive B-1 B cells: constraints on natural autoantibody B cell antigen receptors. J Autoimmun 2007, 29:236-245.
26. Kuniyasu Y., Takahashi T., Itoh M., Shimizu J., Toda G., Sakaguchi S. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000, 12:1145-1155.
27. Dasu T., Qualls J.E., Tuna H., Raman C., Cohen D.A., Bondada S. CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett 2008, 119:103-113.
28. Stamou P., de Jersey J., Carmignac D., Mamalaki C., Kioussis D., Stockinger B. Chronic exposure to low levels of antigen in the periphery causes reversible functional impairment correlating with changes in CD5 levels in monoclonal CD8T cells. J Immunol 2003, 171:1278-1284.
29. Frommer F., Heinen T.J., Wunderlich F.T., Yogev N., Buch T., Roers A., Bettelli E., Muller W., Anderton S.M., Waisman A. Tolerance without clonal expansion: self-antigen-expressing B cells program self-reactive T cells for future deletion. J Immunol 2008, 181:5748-5759.
30. Hippen K.L., Tze L.E., Behrens T.W. CD5 maintains tolerance in anergic B cells. J Exp Med 2000, 191:883-890.
31. Hawiger D., Masilamani R.F., Bettelli E., Kuchroo V.K., Nussenzweig M.C. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004, 20:695-705.
32. Yamazaki S., Steinman R.M. Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J Dermatol Sci 2009, 54:69-75.
33. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
34. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008, 118:3420-3430.
35. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
36. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
37. Watanabe R., Ishiura N., Nakashima H., Kuwano Y., Okochi H., Tamaki K., Sato S., Tedder T.F., Fujimoto M Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010, 184:4801-4809.
38. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009, 182:7459-7472.
39. Lampropoulou V., Hoehlig K., Roch T., Neves P., Calderon Gomez E., Sweenie C.H., Hao Y., Freitas A.A., Steinhoff U., Anderton S.M., et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008, 180:4763-4773.
40. Iwata Y., Matsushita T., Horikawa M., Dilillo D.J., Yanaba K., Venturi G.M., Szabolcs P.M., Bernstein S.H., Magro C.M., Williams A.D., et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
41. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010, 22:761-767.
42. Mizoguchi A., Bhan A.K. A case for regulatory B cells. J Immunol 2006, 176:705-710.
43. Vera J., Fenutria R., Canadas O., Figueras M., Mota R., Sarrias M.R., Williams D.L., Casals C., Yelamos J., Lozano F. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A 2009, 106:1506-1511.
44. Adams E.L., Rice P.J., Graves B., Ensley H.E., Yu H., Brown G.D., Gordon S., Monteiro M.A., Papp-Szabo E., Lowman D.W., et al. Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J Pharmacol Exp Ther 2008, 325:115-123.
45. Sarrias M.R., Farnos M., Mota R., Sanchez-Barbero F., Ibanez A., Gimferrer I., Vera J., Fenutria R., Casals C., Yelamos J., et al. CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci U S A 2007, 104:11724-11729.
46. Lenz L.L. CD5 sweetens lymphocyte responses. Proc Natl Acad Sci U S A 2009, 106:1303-1304.
47. Borrello M.A., Palis J., Phipps R.P. The relationship of CD5+ B lymphocytes to macrophages: insights from normal biphenotypic B/macrophage cells. Int Rev Immunol 2001, 20:137-155.
48. De Bernardis F., Lucciarini R., Boccanera M., Amantini C., Arancia S., Morrone S., Mosca M., Cassone A., Santoni G. Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis. Infect Immun 2006, 74:4282-4294.
49. Calvo J., Places L., Espinosa G., Padilla O., Vila J.M., Villamor N., Ingelmo M., Gallart T., Vives J., Font J., et al. Identification of a natural soluble form of human CD5. Tissue Antigens 1999, 54:128-137.
50. Jamin C., Magadur G., Lamour A., Mackenzie L., Lydyard P., Katsikis P., Youinou P. Cell-free CD5 in patients with rheumatic diseases. Immunol Lett 1992, 31:79-83.
51. Ramos-Casals M., Font J., Garcia-Carrasco M., Calvo J., Places L., Padilla O., Cervera R., Bowen M.A., Lozano F., Ingelmo M. High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjogren's syndrome. Rheumatology (Oxf) 2001, 40:1056-1059.
52. Noh G.W., Lee K.Y. Circulating soluble CD5 in atopic dermatitis. Mol Cells 1998, 8:618-622.
53. Biancone L., Bowen M.A., Lim A., Aruffo A., Andres G., Stamenkovic I. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med 1996, 184:811-819.
54. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., Joosten L.A., Akira S., Netea M.G., Adema G.J. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006, 116:485-494.
55. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., Wang D.Y., Li Y., Wang H.Y., Wang R.F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
56. Crellin N.K., Garcia R.V., Hadisfar O., Allan S.E., Steiner T.S., Levings M.K. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 2005, 175:8051-8059.